Hardavella Georgia, Frille Armin, Sreter Katherina Bernadette, Atrafi Florence, Yousaf-Khan Uraujh, Beyaz Ferhat, Kyriakou Fotis, Bellou Elena, Mullin Monica L, Janes Sam M
4th-9th Department of Respiratory Medicine, 'Sotiria' Athens' Chest Diseases Hospital, Greece.
Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany.
Breathe (Sheff). 2024 Aug 27;20(2):230190. doi: 10.1183/20734735.0190-2023. eCollection 2024 Jun.
Lung cancer screening (LCS) programmes have emerged over recent years around the world. LCS programmes present differences in delivery, inclusion criteria and resource allocation. On a national scale, only a few LCS programmes have been fully established, but more are anticipated to follow. Evidence has shown that, in combination with a low-dose chest computed tomography scan, smoking cessation should be offered as part of a LCS programme for improved patient outcomes. Promising tools in LCS include further refined risk prediction models, the use of biomarkers, artificial intelligence and radiomics. However, these tools require further study and clinical validation is required prior to routine implementation.
近年来，肺癌筛查（LCS）项目在全球范围内纷纷涌现。LCS项目在实施方式、纳入标准和资源分配方面存在差异。在国家层面，只有少数LCS项目已全面建立，但预计会有更多项目相继开展。有证据表明，结合低剂量胸部计算机断层扫描，应将戒烟作为LCS项目的一部分提供给患者，以改善治疗效果。LCS中有前景的工具包括进一步完善的风险预测模型、生物标志物的应用、人工智能和放射组学。然而，这些工具需要进一步研究，并且在常规应用之前需要进行临床验证。
